Webb13 apr. 2024 · J Clin Oncol 30:300–307 CrossRefPubMed Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes HS, Fosså SD, Oldenburg J, Travis LB (2012) Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. WebbNew indication for tucatinib (Tukysa ®; Seagen) in combination with trastuzumab for RAS wild-type, HER2-positive, unresectable or metastatic colorectal cancer that has progressed following chemotherapy (fluoropyrimidine, oxaliplatin, and irinotecan based).
ADVANCES IN TREATMENT OF EPITHELIAL OVARIAN CANCER
Webb19 maj 2016 · He is actively involved in several human clinical trials looking at the prevention of cisplatin ototoxicity that may drastically decrease the number of children developing hearing loss after... WebbPotential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy Export Statistics. Options. Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy. Journal. Free Radical Biology and Medicine quotes from the crucible about hysteria
Kay Chang - Professor - Stanford University School of Medicine
WebbSelect search scope, currently: articles+ all catalog, articles, website, & more in one search; catalog books, media & more in the Stanford Libraries' collections; articles+ journal articles & other e-resources WebbSodium thiosulfate interacts directly with cisplatin to produce an inactive platinum species. Regulatory Status Sodium thiosulfate (e.g., Pedmark) was approved by the U.S. Food and Drug Administration (FDA) on September 20th, 2024, to reduce the risk of ototoxicity associated with cisplatin in pediatric individuals 1 month of age and older with localized, … Webb20 dec. 2024 · Unfortunately, platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer. Each year in the U.S. and … shirt oxford